Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Common Equity (2022)

Historic Common Equity for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to -$54.2 million.

  • ADC Therapeutics' Common Equity fell 15170.78% to -$54.2 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$54.2 million, marking a year-over-year decrease of 15170.78%. This contributed to the annual value of $79.5 million for FY2022, which is 4773668.9% up from last year.
  • ADC Therapeutics' Common Equity amounted to -$54.2 million in Q3 2023, which was down 15170.78% from -$8.6 million recorded in Q2 2023.
  • Over the past 5 years, ADC Therapeutics' Common Equity peaked at $298.0 million during Q1 2021, and registered a low of -$54.2 million during Q3 2023.
  • In the last 5 years, ADC Therapeutics' Common Equity had a median value of $58.6 million in 2022 and averaged $83.8 million.
  • As far as peak fluctuations go, ADC Therapeutics' Common Equity soared by 12415650.27% in 2021, and later tumbled by 15170.78% in 2023.
  • Over the past 5 years, ADC Therapeutics' Common Equity (Quarter) stood at $111156.0 in 2019, then soared by 238.32% to $376059.0 in 2020, then skyrocketed by 1705.76% to $6.8 million in 2021, then soared by 1069.99% to $79.5 million in 2022, then plummeted by 168.19% to -$54.2 million in 2023.
  • Its Common Equity was -$54.2 million in Q3 2023, compared to -$8.6 million in Q2 2023 and $37.7 million in Q1 2023.